NCT02857270

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.

Conditions

• Advanced Cancer
• Metastatic Melanoma
• Metastatic Non-small Cell Lung Cancer
• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	LY3214996	Administered orally
DRUG	Midazolam	Administered orally
DRUG	Abemaciclib	Administered orally
DRUG	Nab-paclitaxel	Administered IV
DRUG	Gemcitabine	Administered IV
DRUG	Encorafenib	Administered orally
DRUG	Cetuximab	Administered IV

Timeline

• Start date: 2016-09-29
• Primary completion: 2021-02-10
• Completion: 2022-10-24
• First posted: 2016-08-05
• Last updated: 2022-11-22

Locations

13 sites across 4 countries: United States, Australia, France, Japan